MILLIPLEX^®人类免疫肿瘤学检查点蛋白多重检测试剂盒，预混17重Panel 1——免疫肿瘤学多重检测

本组套中抗体与任何其他分析物之间的交叉反应性不可检出或可忽略不计。

除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

免疫检查点蛋白是免疫活化的调节因子，在维持免疫稳态、防止自身免疫和参与肿瘤免疫逃逸中发挥着关键作用。这种免疫系统分子在免疫应答中既可以作为激动剂（共刺激检查点分子），也可以作为拮抗剂（共抑制检查点分子）。近年来，检查点抑制剂药物靶向抑制免疫检查点蛋白，如CTLA-4和PD-L1，通过提高抗肿瘤免疫反应和在某些恶性肿瘤的治疗中挽救生命，已被证明可发挥有效的癌症免疫治疗作用。 作为激活受体或抑制受体，免疫检查点蛋白可以表达在免疫细胞和/或肿瘤细胞上。许多免疫检查点蛋白也可表达为可溶性蛋白，进入血液循环和肿瘤以及肿瘤微环境中，作为肿瘤等各种疾病免疫治疗的生物标志物。MILLIPLEX^®人类免疫肿瘤学检查点蛋白多重检测试剂盒(Panel 1)是17重试剂盒，用于同时定量测定血清、血浆和组织/细胞培养样本中的以下全部分析物：BTLA（B、T淋巴细胞弱化因子）、CD27（分化簇27）、CD28（分化簇28）、CD40（分化簇40）、CD80/B7-1（分化簇80/B7-1）、CD86/B7-2（分化簇86/B7-2）、CTLA-4（细胞毒性淋巴细胞活化相关抗原4）、GITRL（TNFRSF18/AITR/GITR受体配体）、GITR（糖皮质激素诱导的肿瘤坏死因子受体）、HVEM（疱疹病毒入侵因子）、ICOS（T细胞可诱导共刺激分子）、LAG-3（淋巴细胞活化基因3）、PD-L1（程序性死亡配体1）、PD-L2（程序性死亡配体2）、PD-1（程序性细胞死亡蛋白1）、TIM-3（T细胞免疫球蛋白黏蛋白3）、TLR-2 (Toll样受体2)。

Immune checkpoint proteins are regulators of immune activation and play a key role in maintaining immune homeostasis, preventing autoimmunity, and are involved in cancer immune escape. These immune system molecules demonstrate the ability to act both as agonists (co-stimulatory checkpoint molecules) or antagonists (co-inhibitory checkpoint molecules) of immune response. Immune checkpoint inhibitor drugs targeting inhibitory immune checkpoint proteins, such as CTLA-4 and PD-L1, have demonstrated efficacy in cancer immunotherapy by improving the antitumor immune response and saving lives in the treatment of many malignancies. Immune checkpoint proteins may express on immune cells and/or tumor cells as activating receptors or inhibitory receptors. Many immune checkpoint proteins are also expressed as soluble forms in circulation and in the tumor and tumor microenvironment and are putative biomarkers for immunotherapy in various diseases including cancer.

96孔板

试剂盒组件的建议储存温度为2 - 8°C。

Luminex is a registered trademark of Luminex Corp

MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

xMAP is a registered trademark of Luminex Corp

MILLIPLEX^® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze 17 analytes in human serum, plasma, and cell culture supernatants.Analytes included: BTLA (B- and T-lymphocyte attenuator), CD27 (Cluster of differentiation 27), CD28 (Cluster of differentiation 28), CD40 (Cluster of differentiation 40), CD80/B7-1 (Cluster of differentiation 80/B7-1), CD86/B7-2 (Cluster of differentiation 86/B7-2), CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), GITRL (Ligand for receptor TNFRSF18/AITR/GITR), GITR (Glucocorticoid-induced TNFR-related protein), HVEM (Herpesvirus entry mediator), ICOS (Inducible T-cell costimulator), LAG-3 (Lymphocyte-activation gene 3), PD-L1 (Programmed death-ligand 1), PD-L2 (Programmed death-ligand 2), PD-1 (Programmed cell death protein 1), TIM-3 (T-cell immunoglobulin and mucin-domain containing-3), TLR-2 (Toll like receptor 2)Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.